Camlipixant is an investigational, twice-daily oral P2X3 receptor antagonist for the treatment of RCC, which is currently being evaluated in the CALM phase III clinical development programme. Given the need for novel and effective medicines for RCC, camlipixant has the potential to be a breakthrough in the treatment landscape.
(RCC is a cough that persists for more than eight weeks despite optimal treatment of any underlying conditions or where there is no identifiable underlying cause. Cough hypersensitivity syndrome – excessive coughing, often in response to relatively innocuous stimuli – is now identified as the primary pathology in RCC. )
For research use only. We do not sell to patients.